Bookmark

Add to MyYahoo RSS

Akorn News

News on Akorn (Ticker: AKRX) continually updated from thousands of sources around the net.

21 hrs ago | AmericanBankingNews.com

Akorn Receives Consensus Rating of "Buy" from Brokerages

Shares of Akorn have received an average rating of "Buy" from the ten brokerages that are covering the company, AnalystRatings.NET reports .

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

Wed Aug 27, 2014

AmericanBankingNews.com

Akorn Director John N. Kapoor Sells 50,000 Shares

Akorn Director John N. Kapoor sold 50,000 shares of Akorn stock on the open market in a transaction that occurred on Tuesday, August 26th.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

Mon Aug 18, 2014

Investor's Business Daily

Stock Futures Steer Higher; Dollar General, Akorn Rising

Dow futures traded ahead 87.1 points. Nasdaq 100 futures were 20.3 points above fair market value.

Comment?

Related Topix: Biotech, Dollar General, Retail, Medicine, Financial Services, Kohlberg Kravis Roberts, Healthcare Industry, Investment Services, Financial Markets, Dollar Tree Stores

Tue Aug 12, 2014

BioSpace

Akorn, Inc. Completes Acquisition Of VersaPharm

Akorn, Inc. , a niche pharmaceutical company, announced today that it has completed its previously announced acquisition of VPI Holdings Corp., the parent company of VersaPharm Incorporated, for $440 million.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Marketing

Mon Aug 11, 2014

AmericanBankingNews.com

Akorn Upgraded to Outperform by Zacks

The firm currently has a $36.90 price target on the stock. Zacks 's price objective points to a potential upside of 7.52% from the company's current price.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

Sat Aug 09, 2014

GuruFocus.com

Weekly CEO Sells Highlight: Akorn Inc, Under Armour Inc, Anadarko Petroleum Corp, and Graphic ...

According to GuruFocus Insider Data , these are the largest CEO sales during the past week: Akorn Inc, Under Armour Inc, Anadarko Petroleum Corp, and Graphic Packaging Holding Co.

Comment?

Related Topix: Anadarko Petroleum, Oil & Gas, Biotech, Medicine, Healthcare Industry, Manufacturing, Industrial Machines, Graphic Packaging, Paper, Abita Springs, LA

Fri Aug 08, 2014

AmericanBankingNews.com

Insider Selling: Akorn CEO Sells 903,659 Shares of Stock

Akorn CEO Rajat Rai sold 903,659 shares of the stock on the open market in a transaction dated Thursday, August 7th.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

Investor's Business Daily

Drugmaker Results Top Views

Actavis' EPS rose 70% to $3.42 on a 34% sales rise to $2.7 bil. EPS rose 43% on a 40% sales gain.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

Tue Aug 05, 2014

Seeking Alpha

Akorn's (AKRX) CEO Raj Rai on Q2 2014 Results - Earnings Call Transcript

Good morning and thank you for joining Akorn, Inc.'s 2014 Second Quarter Conference Call.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Corporate / Securities Law, Law

Investor's Business Daily

Actavis Guidance Disappoints; Akorn Beats And Raises

Actavis' earnings rose 70% over the year-earlier quarter to $3.42 a share, beating analysts' consensus by 5 cents.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Forest Laboratories, Forest Labs

AmericanBankingNews.com

Akorn, Inc. (AKRX) Releases FY14 Earnings Guidance

Akorn, Inc. issued an update on its FY14 earnings guidance on Tuesday morning. The company provided earnings per share guidance of $1.00-1.05 for the period, compared to the Thomson Reuters consensus estimate of $0.85, Analyst Ratings News reports.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

GlobeNewswire

Akorn Reports Preliminary 2014 Second Quarter Results

Akorn, Inc. , a niche generic pharmaceutical company, today reported preliminary financial results for the second quarter ended June 30, 2014.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

Mon Aug 04, 2014

Holtville Tribune

Settlement Preserves Future Competition in Generic Injectable Tuberculosis Drug Market

Pharmaceutical company Akorn, Inc. has agreed to sell its rights to develop, manufacture, and market the generic injectable tuberculosis drug, rifampin, in order to settle FTC charges that Akorn's proposed acquisition of VersaPharm Inc. and its parent company, VPI Holdings Corp., would likely be anticompetitive.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Health, Tuberculosis, Rifampin (generic), Rimactane, Rifadin, Food and Drug Administration

Reuters

Akorn wins U.S. approval to buy VersaPharm

Pharmaceutical company Akorn Inc has won U.S. antitrust approval to buy specialty prescription drug company VersaPharm Inc on condition it sell its rights to a generic tuberculosis drug, the Federal Trade Commission said on Monday.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Health, Tuberculosis

•••
•••
•••
•••
•••

Ashburn Jobs

•••
•••
•••
•••